Victoria Lanski
Acute Care · Reno, NVNPI 1851964381
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Genentech USA, Inc. at 57.1% of the total. Reporting peaked in 2023 at $3,330 and has fallen 94.4% since, to $186 in 2025. Among acute care clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $60.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$3K
- GSK$741
- AstraZeneca$675
- Regeneron Healthcare Solutions, Inc.$264
- Boehringer Ingelheim$188
- Insmed, Inc.$47
- plus $94 from 3 others
Across 1 payment — averaging $34,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$34K
What the payments were for
- Travel & lodging$2,62256%
- Food & beverage$2,05144%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 7 | $2,675 |
| GSK | 36 | $741 |
| AstraZeneca | 18 | $675 |
| Regeneron Healthcare Solutions, Inc. | 4 | $264 |
| Boehringer Ingelheim | 6 | $188 |
| Insmed, Inc. | 2 | $47 |
| Philips North America LLC | 2 | $33 |
| Baxter Healthcare | 1 | $31 |
| ZOLL Respicardia, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$340
- AREXVY$125
- TRELEGY ELLIPTA$103
How this compares
$4,684 in reported general payments places this provider in the 90th percentile of 129 acute care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 328 | $375,449 |
| Spiriva RespimatTiotropium Bromide | 98 | $84,354 |
| Breo ElliptaFluticasone/Vilanterol | 86 | $55,497 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $39,497 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $36,163 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $35,184 |
| Wixela InhubFluticasone Propion/Salmeterol | 67 | $23,989 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $23,496 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $21,387 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $21,066 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,131 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 272 | $8,830 |
| Arnuity ElliptaFluticasone Furoate | 13 | $4,865 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,582 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 28 | $2,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $741 | $470,995474 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $188 | $120,517133 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $675 | $62,99381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 acute care providers in Nevada.
Other acute care in Reno
- Frank TalonReno$6K
- Sarah DeboorReno$5K
- Michael ThompsonReno$4K
- Sarah FarberReno$4K
- Corinne CanaveroReno$4K
- Amelia ManguneReno$3K
- Brynja BowmanReno$3K
- Jeanine PackhamReno$2K
- Christopher HallReno$2K
- Heather CarrollReno$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.